Open AccessAutologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial
Author(s) -
N. Ahmed,
V. Brawley,
M. Hegde,
K. Bielamowicz,
A. Wakefield,
A. Ghazi,
A. Ashoori,
O. Diouf,
C. Gerken,
D. Landi,
M. Kalra,
Zhifei Yi,
C. Rooney,
G. Dotti,
A. Gee,
H. Heslop,
S. Gottschalk,
S. Powell,
R. Grossman,
W. Wels,
Y. Kew,
D. Baskin,
J. Zhang,
P. New,
J. Hicks
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/3ep7-r524
Subject(s) - bispecific antibody , glioblastoma , medicine , clinical trial , cancer research , oncology , immunology , antibody , monoclonal antibody